An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

NCT00092183 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

866

Enrollment

INDUSTRY

Sponsor class

Conditions

Nausea
Vomiting
Breast Neoplasms

Interventions

DRUG: MK0869, aprepitant / Duration of Treatment: 3 days
DRUG: Comparator: ondansetron / Duration of Treatment: 3 days

Sponsor

Merck Sharp & Dohme LLC